GlassScriptPhysician profile
Christopher D Tumpkin
NPI 1528068558
$3,483.22
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $709 · 2021: $629 · 2022: $1,064 · 2023: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $721.32 | 2019-2022 | |
| Genzyme Corporation | $648.27 | 2019-2023 | |
| Glaxosmithkline, LLC. | $473.64 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $289.64 | 2019-2023 | Dupixent |
| Pharming Healthcare, INC. | $194.05 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.78 | 2020-2022 | |
| Optinose US, INC. | $159.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $131.65 | 2019-2022 | |
| Grifols USA, LLC | $90.52 | 2019-2020 | |
| Csl Behring | $87.91 | 2019-2023 | Haegarda |
| Shire North American Group INC | $79.40 | 2019 | |
| Genentech USA, INC. | $71.54 | 2021-2023 | Xolair |
| Kaleo, INC. | $67.43 | 2022-2023 | Auvi-Q |
| Aimmune Therapeutics, INC. | $64.28 | 2020-2022 | |
| Biocryst US Sales Co., LLC | $58.06 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.33 | 2019-2020 | |
| Amgen INC. | $35.19 | 2022-2023 | Tezspire |
| Biocryst Pharmaceuticals, INC. | $25.06 | 2020 | |
| Phadia US INC. | $23.89 | 2022 | |
| Tersera Therapeutics LLC | $22.84 | 2021 | |
| Alk-Abello, INC | $21.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tumpkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.